Prostate Cancer Drugs Global Market Report 2023 – By Type (Hormone Sensitive Prostate Cancer, Hormone Refractory Prostate Cancer), By Therapy (Hormonal Therapy, Chemotherapy , Immunotherapy, Targeted Therapy), By End User (Hospitals, Clinics, Other EndUsers) – Market Size, Trends, And Global Forecast 2023-2032

Diuretic drugs refer to the drugs that help increase the flow of urine by reducing the concentration of sodium and chloride in the body. It helps the body eliminate salt (sodium) and water with these so-called "water tablets." Diuretic drugs include diuril, microzide, and indapamide. The main types of diuretics are osmotic diuretics, carbonic anhydrase inhibitors, loop diuretics, thiazides and thiazide-like diuretics, and aldosterone antagonists. An osmotic diuretic is a form of diuretic that prevents water and sodium from being reabsorbed. They are intravenously administered, pharmacologically inactive compounds. The different routes of administration include intravenous and oral, and they are used in hypertension, glaucoma, heart failure, and kidney stones. It is distributed through various channels, such as hospital pharmacies, independent pharmacies, retail pharmacies, drug stores, and online pharmacies. The global diuretics market is segmented - 1) By Type: Osmotic Diuretics, Carbonic Anhydrase Inhibitors, Loop Diuretics, Thiazides & Thiazide-Like Diuretics, Aldosterone Antagonists 2) By Application: Hypertension, Glaucoma, Heart Failure, Kidney Stones 3) By Distribution: Hospital Pharmacies, Independent Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies 4) By Route of Administration: Intravenous, Oral The global diuretics market size will grow from $0.64 billion in 2022 to $0.67 billion in 2023 at a compound annual growth rate (CAGR) of 4.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global diuretics is expected to grow to $0.75 billion in 2027 at a CAGR of 2.9%. The increase in renal and kidney disorder cases drives the diuretics market. In such cases, the kidney does not function properly increases the need for water pills (diuretic drugs) to maintain a proper flow of urine. The rise in kidney disorders can be attributed to changes in lifestyle such as the consumption of unhealthy food high in calcium and other minerals. For example, in 2021, according to the Centers For Disease Control and Prevention, a US-based government agency, more than 1 in 7 people, that is 15% of US adults,approximately 37 million people, are suffering from chronic kidney diseases. Therefore, increase in renal and kidney disorder cases drives the growth of the diuretics market. Major players in the diuretics market are Merck & Co., Meda Manufacturing GmbH, Pfizer Inc., GlaxoSmithKline, Roche, Aton Pharma Inc., Boehringer Ingelheim GmbH, Novartis AG, and Teva Pharmaceuticals Industries Ltd. The diuretics market is restricted by the stringent regulatory policies governing the market. Several requirements are laid down by the regulatory bodies to manufacture, process, and pack the drugs and the companies should abide by various compliances such as FDA's CGMP regulations, Compliance with European Medicines Agency Regulations, and WHO Guidelines. For instance, the Current Good Manufacturing Practice (CGMP) regulations of the FDA in the USA impose several regulations under 21 CFR parts 314, 210, and 211, concerning the application and licensing of new and generic drugs, regulations for manufacturing, processing, packaging or holding of drugs, and requirements for finished pharmaceuticals respectively. These regulations negatively impact the growth of the market. A new drug delivery technology called the oral nanoparticle delivery technology is developed to improve the pH and intestinal permeability of the diuretic drugs to increase the digesting capability as the majority of these drugs have low water solubility and bioavailability. Drugs such as amlodipine and isradipine having low bioavailability (less number of solvents to get diluted) and high light sensitivity were delivered using Nanoemulsion (dispersion that consists of oil, surfactants, and aqueous phase) as a drug delivery system. Pharmacokinetics (study of how an organism affects a drug) data of both the drugs revealed enhanced stability and bioavailability. For instance, Nanomerics, a pharmaceutical nanotechnology drug delivery company is carrying out R&D in this technology by working on MET (Molecule Envelop Technology) Nanoparticles Oral Delivery. Also, in 2020, a Japanese research team from Kumamoto University developed a new nanocarrier drug delivery technology to enhance the drugs, from moving from the blood into the brain. The manufacturers must comply with the European Medicines Agency’s scientific guidelines on the quality that should be maintained in the manufacturing, processing, and packaging of the drugs and help manufacturers prepare marketing authorization applications. In addition, the International Council for Harmonization (ICH) guidelines lay down the Good Manufacturing Practice (ICHQ7) guide, which states that all the utilities like steam, gases, compressed air, heating, ventilation, and air conditioning could impact the quality of the product (drug). Hence, proper monitoring should be conducted and actions should be taken if limits are exceeded. It has also framed guidelines for Quality Risk Management (ICHQ9) that provide all the risk management methods and tools like FMEA (Failure Mode Effects Analysis), FMECA (Failure Mode, Effects and Criticality Analysis), FTA (Fault Tree Analysis), HACCP (Hazard Analysis and Critically Control Points) and others. In March 2020, AstraZeneca, a UK-based pharmaceutical company, acquired AtnahsPharma for $350 million. Through this acquisition, AstraZeneca gets the commercial rights to various drugs such as Tenoretic (atenolol, chlorthalidone fixed-dose combination), and Tenormin (atenolol), Zestoretic (lisinopril, hydrochlorothiazide fixed-dose combination), Inderal (propranolol), and Zestril (lisinopril). AtnahsPharma is a UK-based company that develops diuretic drugs. North America was the largest region in the diuretics market in 2022. The Middle East is expected to be the fastest-growing region in the global diuretics market share during the forecast period. The regions covered in the global diuretics market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the diuretics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The diuretics market consists of sales of diuril, microzide, and indapamide. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The diuretics market research report is one of a series of new reports from The Business Research Company that provides diuretics market statistics, including diuretics industry global market size, regional shares, competitors with a diuretics market share, detailed diuretics market segments, market trends and opportunities, and any further data you may need to thrive in the diuretics industry. This diuretics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The erectile dysfunction (ED) drugs refer to the drugs that are used to improve the effects of nitric oxide, a substance your body naturally generates that relaxes penile muscles, to treat erectile dysfunction. Erectile dysfunction is the inability to achieve or keep up a penile erection in men. The different types of drugs in erectile dysfunction (ED) drugs are sildenafil citrate, mirodenafil, and vardenafil. Sildenafil is a drug that is used to treat erectile dysfunction and pulmonary arterial hypertension. It is offered under the trade names Viagra and others. It’s unknown whether it’s effective in treating female genital dysfunction. The different routes of administration include Oral, topical, and injections and are used by hospital pharmacies, retail pharmacies, and online pharmacies. The global drugs for erectile dysfunction market is segmented - 1) By Drugs: Sildenafil Citrate, Mirodenafil, Vardenafil 2) By End users: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 3) By Mode of Administration: Oral, Topical, Injections The global drugs for erectile dysfunction market size will grow from $3.21 billion in 2022 to $3.25 billion in 2023 at a compound annual growth rate (CAGR) of 1.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global drugs for erectile dysfunction market size is expected to grow to $3.36 billion in 2027 at a CAGR of 0.8%. The drastic increase in the number of chronic diseases drives the erectile dysfunction drug market. Erectile dysfunction is mainly caused by chronic diseases resulting from a sedentary lifestyle such as cardiovascular diseases, diabetes, obesity, and high blood pressure. According to WHO, the prevalence of chronic diseases is expected to grow by 57% by the end of the year 2020. Prevalence of chronic diseases increases the chances of erectile dysfunction among men, thereby driving the erectile dysfunction drug market. Major players in the erectile dysfunction (ED) drugs market are Eli Lilly and Co., Pfizer, Bayer AG, Dong-A Pharmaceutical Co. Ltd., Vivus, Meda Pharmaceuticals, Apricus Biosciences, Cristália, S.K. Chemicals Co and Teva Pharmaceutical Industries Ltd. Patients suffering from erectile dysfunction do not seek treatment owing to factors such as lack of education, lack of awareness, strong religious beliefs, social taboo, and low socioeconomic status. These factors are responsible for the patients suffering from erectile dysfunction rejecting or avoiding the treatment. For example, according to a survey conducted by Opinium Research in February 2020, just 27% out of the total 2,006 men surveyed were aware that erectile dysfunction could be linked to high blood pressure or elevated cholesterol while just 22% of men surveyed were aware that erectile dysfunction is often associated with diabetes. These factors restrain the growth of the erectile dysfunction drug market. New drug delivery techniques such as the use of pellets and creams are being implemented by many companies in the erectile dysfunction drugs market. Pellets and creams will have more efficacy and performance in erectile dysfunction and these are also more effective and safer to use. These benefits from drug delivery techniques will increase the scope of the erectile dysfunction drug market. For example, In September 2022, Lupin, an India-based pharmaceutical company launched Sildenafil for oral suspension, 10 mg/mL with the approval of the United States Food and Drug Administration (FDA). This drug is for erectile dysfunction with unique dosages. Medicines are authorized by regulatory bodies based on quality, safety, and efficacy to make sure that medicines are of standard quality and gives positive benefit. Companies are mandated to submit the documentation for the standard quality before applying for authorization. The safety and efficacy of medicines should be demonstrated by clinical trials for all new medicines by the companies. Competent authorities will assess this data before authorizing the drugs. In Europe, the European Medicines Agency (EMA) assesses the drugs for centrally authorized products. North America was the largest region in the erectile dysfunction (ED) drugs market in 2022. Middle East is expected to be the fastest-growing region in the global drugs for erectile dysfunction market during the forecast period. The regions covered in the global erectile dysfunction (ED) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the erectile dysfunction (ED) drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The erectile dysfunction (ED) drugs market consists of sales Sildenafil (Viagra), vardenafil (Levitra, Staxyn), tadalafil (Cialis) and avanafil (Stendra). Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The erectile dysfunction (ED) drugs market research report is one of a series of new reports from The Business Research Company that provides erectile dysfunction (ED) drugs market statistics, including erectile dysfunction (ED) drugs industry global market size, regional shares, competitors with erectile dysfunction (ED) drugs market share, detailed erectile dysfunction (ED) drugs market segments, market trends and opportunities, and any further data you may need to thrive in the erectile dysfunction (ED) drugs industry. This erectile dysfunction (ED) drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Drugs for immunotherapy refer to a kind of medication that offers treatment to either stimulate or suppress the immune system in order to aid the body's protection against cancer, infection, and other disorders. Your immune system is assisted in fighting cancer via immunotherapy, a sort of cancer treatment. The body's immune system aids in the fight against infections and other disorders. The main types of drugs for immunotherapy are monoclonal antibodies, interferons, interleukins, vaccines, checkpoint inhibitors, and others. Monoclonal antibodies are created by cloning a single white blood cell. Every subsequent antibody generated in this manner may be traced back to a single parent cell. The different areas of therapy include cancer, autoimmune and inflammatory diseases, infectious diseases, and others, and they are used by various sectors such as hospitals and clinics, ambulatory surgical centers, and others. The global drugs for immunotherapy market is segmented - 1) By Type: Monoclonal Antibodies, Interferons, Interleukins, Vaccines, Checkpoint Inhibitors, Other Types 2) By Therapy Area: Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases, Other Therapy Areas 3) By End User: Hospitals & Clinics, Ambulatory Surgical Centers, Other End Users The global drugs for immunotherapy market size grew from $208.56 billion in 2022 to $231.12 billion in 2023 at a compound annual growth rate (CAGR) of 10.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global drugs for immunotherapy is expected to grow from $349.53 billion in 2027 at a CAGR of 10.9%. The drugs for immunotherapy market is being driven by rising incidences of cancer globally. The major causes of most cancers include obesity, smoking, alcohol, and improper eating habits. For instance, in February 2022, according to a report shared by the WHO, a Switzerland-based specialized agency of the United Nations responsible for international public health, roughly 10 million deaths, or nearly one in six deaths, will be caused by cancer in 2020, making it the top cause of death globally. Breast, lung, colon, rectum, and prostate cancers are the most prevalent types of cancer. The use of tobacco, having a high body mass index, drinking alcohol, eating few fruits and vegetables, and not exercising account for about one-third of cancer-related fatalities. The rising incidences of cancer are expected to increase the demand for immunotherapy drugs driving the drugs for immunotherapy market growth. Major players in the drugs for immunotherapy market are F. Hoffmann-La Roche Ltd., Novartis AG, Amgen, Inc., AbbVie, Inc., and Merck & Co. Inc., GlaxoSmithKline, Eli Lilly and Company, Bristol-Myers Squibb, AstraZeneca PLC., Johnson & Johnson, and UbiVac. The high cost of drugs for the immunotherapy market is acting as a restraint on the drugs for the immunotherapy market as a smaller number of patients can afford the treatment. Immunotherapy drugs are expensive as they are made specifically for each patient, and investment costs in research and development are high. For instance, Novartis’ Kymriah and Gilead Sciences’ Yescarta are two immunotherapy treatments that cost between $373,000 and $475,000 per patient, depending on the type of cancer. The Yervoy (ipilimumab) drug from Bristol-Myers Squibb, for the treatment of melanoma, a type of skin cancer, costs $120,000 per course of treatment. The high cost of immunotherapy drugs makes them unaffordable, thereby affecting the drugs for immunotherapy market growth. Manufacturers of drugs for immunotherapy market are increasingly collaborating or partnering with other companies to share technology, resources, and product knowledge and expand the business. For example, Illumina Inc. and Bristol-Myers Squibb (BMS) collaborated to utilise Illumina’s next-generation sequencing (NGS) technology to develop and commercialize in-vitro diagnostic (IVD) assays in support of Bristol-Myers Squibb's oncology portfolio. Allogene Therapeutics Inc. and Pfizer Inc. entered into an asset contribution agreement to use Pfizer’s portfolio of assets related to allogeneic CAR-T therapy. Manufacturers of drugs for immunotherapy market are governed by various regulatory bodies, such as the Food and Drug Administration in the USA. The Food and Drug Administration (FDA) regulates drugs and biologics under the authority granted to it by the Federal Food, Drug, and Cosmetic Act (FD&C Act) and its amendments. Under this authority, FDA regulates the pre-market testing and marketing approval for all immunotherapeutic agents, either as drugs or biologics, depending on the source and function of the investigational agent. Immunotherapeutic products that are regulated as biologics include antibodies and proteins, and some nucleic acids. In August 2020, Bristol Myers Squibb, a US-based pharmaceutical company that manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis, and psychiatric disorders, acquired Dragonfly Therapeutics’ investigational immunotherapy program for $475 million. Through this acquisition, Bristol Myers Squibb will be granted Dragonfly’s extended half-life cytokine DF6002, a monovalent IL-12 immunoglobulin Fc. Dragonfly Therapeutics, Inc. is a US-based discovery-stage company developing drugs to stimulate immune responses against cancer. North America was the largest region in the immunotherapy market in 2022. Middle East is expected to be the fastest growing region in the drug for immunotherapy market report during the forecast period. The regions covered in the drugs for immunotherapy industry report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the drugs for immunotherapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, USA. The drugs for immunotherapy market consist of sales of cytokines, CAR T-cell therapy, and cancer treatment vaccines. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The drugs for immunotherapy market research report is one of a series of new reports from The Business Research Company that provides drugs for immunotherapy market statistics, including drugs for immunotherapy industry global market size, regional shares, competitors with drugs for immunotherapy market share, detailed drugs for immunotherapy market segments, market trends and opportunities, and any further data you may need to thrive in the drugs for immunotherapy industry. This drug for immunotherapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The drug benign prostatic hypertrophy refers to benign prostatic hypertrophy drugs that are used to treat enlarged prostate glands by relaxing bladder neck muscles and muscle fibres in the prostate, making urination easier. Benign Prostatic Hypertrophy is commonly seen in men older than 50. The main types of drugs for benign prostatic hypertrophy are alpha-blockers, 5-alpha reductase inhibitors, phosphodiesterase-5 inhibitors, and others. Alpha-blockers, commonly known as "blockers" or "adrenoreceptor antagonists," are a type of pharmaceutical drug that works by blocking adrenergic receptors. The different sectors include hospital pharmacies, retail pharmacies, and others and are distributed through various channels, such as hospital pharmacies, retail pharmacies, and online pharmacies. The global drugs for benign prostatic hypertrophy market is segmented - 1) By Type: Alpha Blocker, 5-alpha Reductase Inhibitor, Phosphodiesterase-5 Inhibitor, Other Types 2) By End User: Hospital Pharmacies, Retail Pharmacies, Other End-Users 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies The global drugs for benign prostatic hypertrophy market size will grow from $6.45 billion in 2022 to $6.86 billion in 2023 at a compound annual growth rate (CAGR) of 6.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global drugs for benign prostatic hypertrophy is expected to grow to $8.18 billion in 2027 at a CAGR of 4.5%. The rising male geriatric population globally is driving the growth of drugs for benign prostatic hypertrophy market for Benign Prostatic Hypertrophy drugs as the condition is commonly seen in men aged over 50 years. According to the United Nations' 2019 World Population Ageing Report, the number of people aged 65 years or above was 703 million in 2019 and is expected to double to around 1.5 billion by 2050. According to the National Institute of Health (NIH), Benign Prostatic Hyperplasia affects around 50% of men aged between 51 and 60 years and up to 90% of men aged over 80 years. Major players in the drugs for benign prostatic hypertrophy market are Allergan PLC., Astellas Pharma Inc., Boehringer Ingelheim, Eli Lilly and Company, GlaxoSmithKline PLC., Teva Pharmaceutical Industries Limited, Sanofi, Nymox Pharmaceutical Corporation, and AEternaZentaris Inc. Increasing adoption of minimally invasive surgeries due to advancements in technology is restraining the growth of the Benign Prostatic Hyperplasia drugs market. Minimally invasive surgeries cause less pain and are generally conducted on an outpatient basis. This eliminates the need to consume Benign Prostatic Hyperplasia drugs, acting as a restraint on the market. Some of the minimally invasive surgeries used to treat Benign Prostatic Hyperplasia include laparoscopic prostatectomy, transurethral microwave thermotherapy (TUMT), and transurethral needle ablation (TUNA). Combination drugs are increasingly being used in the treatment of Benign Prostatic Hypertrophy as they are more effective and help prevent disease progression. A combination drug includes two or more active pharmaceutical ingredients (APIs) combined in a single dosage form. These drugs reduce the development of drug resistance, have fewer side effects, and low treatment failure rate. For instance, Duodart, a combination of dutasteride and tamsulosin hydrochloride is increasingly being prescribed for the treatment of Benign Prostatic Hypertrophy. Benign prostatic hypertrophy drug manufacturers globally are regulated by various regulatory bodies. For instance, in the European Union, the EU legislation authorizes medicines based on quality, safety, and efficacy. Companies are mandated to submit compliance documentation for suitable quality before applying for authorization. Manufacturers are required to demonstrate the safety and efficacy of drugs using clinical trial data, which will be assessed by competent authorities before authorizing for sale. North America was the largest region in the drugs for benign prostatic hypertrophy market in 2022. Middle East is expected to be the fastest-growing region in the global drugs for benign prostatic hypertrophy market share. The regions covered in the global drugs for benign prostatic hypertrophy market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the drugs for benign prostatic hypertrophy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The drugs for benign postratic hypertrophy market consists of sales of alfuzosin (Uroxatral), doxazosin (Cardura), tamsulosin (Flomax) and silodosin (Rapaflo). Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The drugs for benign prostatic hypertrophy market research report is one of a series of new reports from The Business Research Company that provides drugs for benign prostatic hypertrophy market statistics, including drugs for benign prostatic hypertrophy industry global market size, regional shares, competitors with drugs for benign prostatic hypertrophy market share, detailed drugs for benign prostatic hypertrophy market segments, market trends and opportunities, and any further data you may need to thrive in the drugs for benign prostatic hypertrophy industry. This drugs for benign prostatic hypertrophy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The genito-urinary drugs market consists of sales of genito-urinary drugs and related services by entities (organizations, sole traders and partnerships) that produce genito-urinary drugs to treat genito- urinary diseases such as urinary tract infections, male reproductive diseases, voiding diseases, female reproductive diseases, glomerular disorders, urinary calculi, cystic kidney disease, Reno vascular diseases, benign prostate diseases, and other related diseases. This industry includes establishments that produce infertility drugs, hormonal contraceptives, erectile dysfunction drugs and hormonal replacement drugs to treat infertility, infections and prevent pregnancy. It also consists of establishments which produce drugs for benign prostatic hypertrophy, drugs for urinary incontinence and overactive bladder, diuretics to treat urinary calculi, glomerular disorders and other urinary disorders. The main types of genito-urinary drugs are hormonal contraceptives, drugs for benign prostatic hypertrophy, drugs for infertility, drugs for erectile dysfunction, drugs for urinary incontinence and overactive bladder, drugs for infections and others, drugs for hormonal replacement therapy and diuretics. Hormonal contraceptives are medications or devices that reduce the likelihood of becoming pregnant. The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs. The various mode of purchase includes prescription-based drugs and over-the-counter drugs which are distributed by hospital pharmacies, retail pharmacies/ drug stores, and others. The global genito-urinary drugs market size is expected to grow from $40.40 billion in 2021 to $42.75 billion in 2022 at a compound annual growth rate (CAGR) of 5.8%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The genito-urinary drugs market is expected to reach $63.83 billion in 2026 at a CAGR of 10.5%. The aging population profile of most countries contributed to the growth of the gastrointestinal drugs market. The increase in patient pool due to rising geriatric population globally, contributed significantly to the growth of the market during the historic period. According to the WHO, by 2030, one in every six people on the planet will be 60 or older. The proportion of the population aged 60 and up will rise from 1 billion in 2020 to 2.2 billion by 2050. This rise in the geriatric population increased the demand for medical care and drove the healthcare expenditure. This has led to increased demand for pharmaceuticals products, significantly impacting market growth during this period. Regulatory agencies and federal governments adopted stringent regulations and took a tough stance on drug pricing by pharmaceutical companies during the historic period. Pharmaceutical companies faced criticism from politicians, patients and physicians over high pricing of some medicines and drugs. Moreover, companies had to sell drugs and medicines at subsidized rates to government hospitals, doctors and clinics, further effecting companies’ revenues. This led to drug manufacturing companies operating on a reduced profit margin, which negatively impacted the attractiveness of the genito-urinary drugs industry in the historic period. Pharmaceutical companies are investing in development of new class drugs for treating overactive bladders (OAB). Earlier anti-muscarinic agents have been used for the treatment of OAB. Going forward, the market is expected to be driven by a new class of drug known as beta-3 adrenergic agonists that has been increasingly used to treat OAB. Beta-3 adrenergic agonists are drugs which cause the bladder muscles to relax without causing side effects such as dry mouth. For instance, In December 2019, GEMTESA's new drug application (NDA) was submitted to the US Food and Drug Administration (FDA), and it was accepted for review in March 2020. GEMTESA ® is a beta-3 adrenergic agonist used to treat overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and urinary frequency. Major companies in the genito-urinary drugs market include Sanofi S.A, GlaxosmithKline, AstraZeneca, AbbVie, Reckitt, Benckiser Group plc, Astellas Pharma Inc., Otsuka Holdings Co ltd, Pfizer Inc., Merck KGaA and Daiichi Sankyo Company. North America was the largest region in the genito-urinary market in 2021. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the genito-urinary drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the dermatology drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam. The global genito-urinary drugs market is segmented - 1) By Type: Hormonal Contraceptives, Drugs for Benign Prostatic Hypertrophy, Drugs for Infertility, Drugs for Erectile Dysfunction, Drugs for Urinary Incontinence and Overactive Bladder, Drugs for Infections and Others, Drugs for Hormonal Replacement Therapy, Diuretics 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others 3) By Route of Administration: Oral, Parenteral, Others 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs

The dermatology drugs market consists of sales of dermatology drugs by entities (organizations, sole traders and partnerships) that produce dermatology drugs to treat skin diseases. This industry includes establishments that produce drugs to treat diseases such as rosacea, dermatitis, hyperhidrosis, androgenic alopecia, acne drugs, microbial infections and other skin disorders. The main types of dermatology drugs are acne drugs, dermatitis, psoriasis, and other drugs for dermatology diseases. Psoriasis is a skin condition that causes red, itchy scaly patches on the knees, elbows, trunk, and scalp. Hypolipidemic drugs are a diverse class of medications used to treat high levels of fats (lipids) in the blood, such as cholesterol (hyperlipidemia). The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs. The various mode of purchase includes prescription-based drugs and over-the-counter drugs which are distributed by hospital pharmacies, retail pharmacies/ drug stores, and others. The global dermatology drugs market size is expected to grow from $49.55 billion in 2021 to $54.54 billion in 2022 at a compound annual growth rate (CAGR) of 10.1%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The dermatology drugs market is expected to reach $117.82 billion in 2026 at a CAGR of 21.2%. The dermatology drugs market was mainly driven by rapid growth in emerging markets in the historic period. Emerging markets growth was aided by rising disposable income, stable political environment and increasing foreign investments in these countries. For instance, according to the IMF, China’s GDP growth rate was 2.3% in 2020. Additionally, according to the World Economic Outlook Reports by the IMF, the global growth is 6% in 2021 and expected to be 4.4% in 2022. Thus, strong economic growth boosted the demand for dermatology drugs and this drove the market during the historic period. High costs associated with drugs is a major issue faced by citizens of many countries. Pressure to contain costs and demonstrate value is widespread. Political uncertainty and persistent economic stress in numerous countries are calling into question the sustainability of public health care funding. In less wealthy countries, lack of cost-effective drugs has influenced the health conditions of the population and has led to a low average life expectancy. As a result, in countries such as Chad, Macedonia, Serbia, the pharmaceutical companies are faced with the pressure of reducing the price of drugs. The high costs associated with drugs are putting pressure on the revenues of dermatology drugs manufacturers. Drug manufacturing companies are using genome testing (genetic diagnosis) to reduce the time and costs spent in clinical trials. A clinical trial is a complex process and it often takes months for a drug to be available in the market. This deprives patients of cost-effective treatment. Researchers in the Rockefeller University used genomic testing and data analytics to predict the response of psoriasis patients for a given treatment. Genomic testing algorithms collect gene-expression data from skin biopsies and detect activity in 50,000 different genes. This technique can predict the response of a patient with an accuracy of 95% and within 12 weeks, thus saving significant time for clinical trials and the launch of new drugs. Major companies in the dermatology drugs market include Amgen, Reckitt Benckiser Group plc, AbbVie, Galderma S.A., LEO Pharma A/S, Bayer AG, GlaxosmithKline, Eli Lilly And Company, Novartis AG and Perrigo Company Plc. North America was the largest region in the dermatology drugs market in 2021. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the dermatology drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the dermatology drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam. The global dermatology drugs market is segmented - 1) By Type: Acne Drugs, Dermatitis, Psoriasis, Other Drugs for Dermatology Diseases 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others 3) By Route of Administration: Oral, Parenteral, Others 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs

The cardiovascular drugs market consists of sales of cardiovascular drugs by entities (organizations, sole traders and partnerships) that produce cardiovascular drugs to treat cardiovascular diseases. This industry includes establishments that produce anti-hypertensive drugs to prevent heart failure by controlling blood pressure and hypolipidemic drugs that reduce lipid and lipoprotein levels in the blood. It also consists of establishments which produce antithrombotic drugs to treat arterial and venous thrombosis. The main types of cardiovascular drugs market are anti-hypertensive drugs, hypolipidemics, anti thrombotics, and other drugs for cardiovascular diseases (congestive heart failure, anti-arrhythmic and anti-anginal drugs). Hypolipidemic drugs are a diverse class of medications used to treat high levels of fats (lipids) in the blood, such as cholesterol (hyperlipidemia). The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs. The various mode of purchase includes prescription-based drugs and over-the-counter drugs which are distributed by hospital pharmacies, retail pharmacies/ drug stores, and others. The global cardiovascular drugs market size is expected to grow from $146.51 billion in 2021 to $153.60 billion in 2022 at a compound annual growth rate (CAGR) of 4.8%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The cardiovascular drugs market is expected to reach $205.71 billion in 2026 at a CAGR of 7.6%. The rise in sedentary jobs, busy lifestyles and changing consumer preferences are affecting the disease profile of the world population, especially non-communicable diseases such as cancer, diabetes and cardiovascular diseases. Long working hours, less physical activity, and unhealthy eating and drinking habits are major causes of cardiovascular diseases including hypertension. According to the World Health Organization, chronic disease prevalence is rose by 57% globally, in the year 2020. These factors are expected to increase the patient pool globally, thereby driving the cardiovascular drugs market during the forecast period. High costs associated with drugs is a major issue faced by citizens of many countries. Pressure to contain costs and demonstrate value is widespread. Political uncertainty and persistent economic stress in numerous countries are calling into question the sustainability of public health care funding. In less wealthy countries, lack of cost-effective drugs has influenced the health conditions of the population and has led to a low average life expectancy. As a result, in countries such as Chad, Macedonia, Serbia, the pharmaceutical companies are faced with the pressure of reducing the price of drugs. The high costs associated with drugs are putting pressure on the revenues of cardiovascular drugs market manufacturers. NOACs are gaining wider acceptance and are replacing traditionally used anti-coagulants such as Warfarin and Heparin. Anti-coagulants have long been used in prevention of thrombus formation in patients suffering with cardiovascular diseases. Use of NOACs makes it easier for patients to continue therapy post discharge as opposed to injections of Heparin and Warfarin which need medical assistance for administration. Some of the NOACs include Pradaxa (dabigatran etexilate) from Boehringer Ingelheim, Xarelto (rivaroxaban) from Janssen, and Eliquis (apixaban) from Bristol-Myers Squibb. Major companies in the cardiovascular drugs market include Medtronic Inc., Boston Scientific Corporation, Abbott Laboratories, Edwards Lifesciences, Cardinal Health, Inc., Johnson & Johnson, Terumo Corporation, Getinge Group, Teleflex Inc. and Becton Dickinson. North America was the largest region in the cardiovascular drugs market in 2021. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the cardiovascular drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cardiovascular drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam. The global cardiovascular drugs market is segmented - 1) By Type: Anti-Hypertensive Drugs, Hypolipidemics, Anti Thrombotics, Other Drugs for Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrhythmic and Anti-Anginal Drugs) 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others 3) By Route of Administration: Oral, Parenteral, Others 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs

The musculoskeletal disorders drugs market consists of sales of musculoskeletal disorders drugs and related services by entities (organizations, sole traders and partnerships) that produce musculoskeletal disorders drugs to treat musculoskeletal disorders such as arthritis, osteoporosis, osteomalacia, and other disorders. This industry includes establishments that produce drugs to treat rheumatoid arthritis, muscle relaxants to reduce muscle pain, and other drugs used in treating osteoarthritis, analgesics drugs, immunosuppressive. Some of the major drugs in the market include Piroxicam Glaxo, Dolonex, Felden, and Piroxicam Pfizer. The main types of musculoskeletal disorders drugs are drugs for rheumatoid arthritis, muscle relaxants and other musculoskeletal disorders drugs. A muscle relaxant is a medication that causes muscle contractions to cease. The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs. The various mode of purchase includes prescription-based drugs and over-the-counter drugs which are distributed by hospital pharmacies, retail pharmacies/ drug stores and others. The global musculoskeletal disorders drugs market size is expected to grow from $897.45 billion in 2021 to $104.03 billion in 2022 at a compound annual growth rate (CAGR) of 6.8%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The musculoskeletal disorders drugs market is expected to reach $163.94 billion in 2026 at a CAGR of 12%. The aging population profile of most countries contributed to the growth of the musculoskeletal disorders drugs market. The increase in patient pool due to rising geriatric population globally, contributed significantly to the growth of the market during the historic period. According to the WHO, by 2030, one in every six people on the planet will be 60 or older. The proportion of the population aged 60 and up will rise from 1 billion in 2020 to 2.1 billion by 2050. This rise in the geriatric population increased the demand for medical care and drove the healthcare expenditure. This has led to increased demand for pharmaceuticals products, significantly impacting market growth during this period. Regulatory changes are likely to lead to increased costs relating to new product development and service offerings to clients. These changes are related to data protection such as the European Union's General Data Protection Regulation (GDPR), changes to drug approval procedures and other regulatory changes. For instance, according to a study on 100 Data Privacy and Data Security statistics for 2020, GDPR compliance is a top priority for 58% of European companies. The GDPR regulation is a EU law on data protection and privacy of individuals residing the European Union and the European Economic Area (EEA). It also regulates data anonymization thus maintaining integrity of data dealing with patients and other clinical trial studies. The potential loss of revenue due to delays in product release and additional costs incurred due to stringent approval processes puts strain to investments relating to new product development, thereby affecting the growth of the musculoskeletal disorders drugs market. Going forward, the market for muscle relaxants is expected to increase with the rise in combination therapy. Combination therapy involves use of more than one medication or drug to treat a disease. These combinational therapies reduce the frequency of drug administration. For instance, in May 2019, Galt Pharmaceuticals has submitted a Supplemental Abbreviated New Drug Application to the U.S. Food and Drug Administration for Orphengesic Forte an oral formulation of aspirin, caffeine, and orphenadrine for the treatment of pain caused due to musculoskeletal disorders. Major companies in the musculoskeletal disorders drugs market include Sanofi S.A, Pfizer Inc., Bristol-Myers Squibb, Eli Lilly And Company, Mitsubishi Tanabe Pharma Corporation, Horizon Therapeutics plc, Procter & Gamble, Eisai Co. Ltd, Biogen Inc and Sino Biopharmaceutical. North America was the largest region in the musculoskeletal disorders drugs market in 2021. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the musculoskeletal disorders drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the musculoskeletal disorders drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam. The global musculoskeletal disorders drugs market is segmented - 1) By Type: Drugs for Rheumatoid Arthritis, Muscle Relaxants, Other Musculoskeletal Disorders Drugs 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others 3) By Route of Administration: Oral, Parenteral, Others 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs